...
首页> 外文期刊>International journal of antimicrobial agents >Molecular characterisation of cyp51A and cyp51B genes coding for P450 14 alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus
【24h】

Molecular characterisation of cyp51A and cyp51B genes coding for P450 14 alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus

机译:伏立康唑抗性黄曲霉实验室分离株编码P450 14α-羊毛甾醇脱甲基酶A(CYP51Ap)和B(CYP51Bp)的cyp51A和cyp51B基因的分子表征

获取原文
获取原文并翻译 | 示例
           

摘要

Aspergillus flavus is the second most common Aspergillus spp. causing invasive infections in immunocompromised patients. Extensive prophylactic use of voriconazole (VCZ) in immunocompromised patients may enhance the selection of VCZ-resistant clinical isolates of A. flavus, compromising the effectiveness of this antifungal drug against A. flavus infection. To study triazole resistance, we selected A. flavus isolates in the laboratory showing reduced in vitro susceptibility to VCZ. The cyp51A and cyp51B genes coding for P450 14 alpha-sterol demethylases A (CYP51Ap) and B (CYP51Bp) were characterised to examine possible drug target modification-dependent resistance to VCZ in this fungus. High-molecular-weight DNA was isolated from 10 A. flavus isolates showing in vitro resistance to VCZ (minimum inhibitory concentration (MIC) range 4-32 mu g/mL) as well as from the drug-susceptible parent isolate X26728 (MIC = 1 mu g/mL). The cyp51A and cyp51B genes were cloned and the nucleotide sequences were determined. A comparison of the deduced amino acid sequences of CYP51Ap from 10 VCZ-resistant isolates with that of the drug-susceptible parent showed no amino acid variation in six of the ten isolates. CYP51Ap from isolates Afl-VCZ6 and Afl-VCZ46 showed a K197N change, CYP51Ap from isolate Afl-VCZ114 showed Y132N and T469S changes, whereas that from isolate Afl-VCZ45 showed K197N, D282E and M288L changes. These results suggest that VCZ-resistant A. flavus isolates can be readily isolated in the laboratory under selection pressure. Multiple mechanisms, including drug target modi. cation, may be responsible for the in vitro resistance of A. flavus to VCZ. Published by Elsevier B. V. on behalf of International Society of Chemotherapy
机译:黄曲霉是第二种最常见的曲霉。在免疫力低下的患者中引起侵入性感染。在免疫功能低下的患者中广泛预防性使用伏立康唑(VCZ)可能会增强抗VCZ的黄曲霉临床分离株的选择,从而损害该抗真菌药对抗黄曲霉感染的有效性。为了研究对三唑的抗性,我们在实验室中选择了黄曲霉分离株,这些分离株显示出对VCZ的体外敏感性降低。编码P450 14α-固醇脱甲基酶A(CYP51Ap)和B(CYP51Bp)的cyp51A和cyp51B基因的特征在于检查这种真菌对VCZ的可能的药物靶向修饰依赖性耐药性。从显示出对VCZ的体外抗性(最小抑菌浓度(MIC)范围为4-32μg / mL)的10种黄曲霉分离株以及对药物敏感的母体分离株X26728(MIC = 1微克/毫升)。克隆了cyp51A和cyp51B基因,并确定了核苷酸序列。从10个抗VCZ的分离株中推导的CYP51Ap氨基酸序列与对药物敏感的亲本的推导氨基酸序列的比较显示,在十个分离物中的六个中没有氨基酸变化。分离株Afl-VCZ6和Afl-VCZ46的CYP51Ap显示K197N变化,分离株Afl-VCZ114的CYP51Ap显示Y132N和T469S变化,而分离株Afl-VCZ45的CYP51Ap显示K197N,D282E和M288L变化。这些结果表明,在选择压力下,可以容易地在实验室中分离出抗VCZ的黄曲霉。多种机制,包括药物靶向方法。阳离子可能是黄曲霉对VCZ的体外抗药性的原因。由Elsevier B. V.代表国际化学疗法协会出版

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号